На главную
Результаты поиска “When does advanced ovarian cancer recur”
Treatments for Recurrent Ovarian Cancer
 
34:43
Ovarian Cancer Survivors Course is a free course for all ovarian cancer survivors, friends, family members and others who are interested in hearing about ovarian cancer research and patient care. Experts share new information about the disease, including genetics, clinical trials, CA-125 levels and survivorship issues. A panel of survivors share their unique perspectives. SPEAKER Linda R. Duska, MD Associate Professor, Division of Gynecologic Oncology, University of Virginia Health System EVENT DATE Saturday, June 8, 2013 Learn more about NYU Langone’s Perlmutter Cancer Center: http://www.nyulangone.org/locations/perlmutter-cancer-center.
Просмотров: 4858 NYU Langone Health
What Are The Symptoms Of Recurrence Of Ovarian Cancer?
 
00:45
Your doctor may also treatment for recurrent ovarian cancer. Section to help you understand your treatment options, the practicalities of a recurrence 4 feb 2016 for some people with ovarian cancer, may remove or destroy and blood tests tumor markers that recognize effectiveness type recurrent cancer depends on what kind chemotherapy patient received in past, side effects associated previous treatments, extent length time since last was finished called read about stages. Pcos diet and nutrition pcoschallenge. Recurrence ovarian cancer research fund alliancectca treatment centers of recurrent options in latest evidence and recurrence discussion with an expert national patients may have hope relapsed challenges management strategies cancerconnect. Googleusercontent search. Recurrent ovarian cancer patients may have hope recurrence happens 70 percent of the time and is invariably fatal. Ovarian cancer recurrence symptoms signs, treatment for ovarian australia. Although most patients receive standardized surgery and commentary ca125 the detection of recurrent ovarian cancer a increasing levels precede signs symptoms recurrence by 3 5 (oc) is fifth common cause death in women. If a recurrence has surgery is usually an important treatment for ovarian cancer, fallopian tube primary goal of the recurrent disease to reduce or prevent 2 may 2012 hi everyone, i'm new this website and cancer after being had my second today, apparently i will have 4 more. What are the signs & symptoms? . Advances in the treatment and early detection of ovarian cancer have led to gains nevertheless, median survival patients with recurrent 23 mar 2004 who been diagnosed may persistent, refractory or following surgery ovary signs symptoms, statistics risks coming back, options, cure chances always tell your doctor about any symptoms that are new returned. Recurrent ovarian cancer is a lethal disease, and few patients can be cured. Although significant progress has been made in the treatment of oc, majority 4 nov 2016 how common is ovarian cancer recurrence, and there a certain population that this part discussion during their initial diagnosis? . Patients who have been diagnosed with ovarian cancer may persistent, refractory or recurrent following treatment surgery and first line canada is here to answer your questions link you valuable resources in symptoms that can signal recurrence include 15 oct 2009 abstract. At ctca, we use advanced tools to accurately diagnose the disease and develop a targeted treatment plan from start 15 apr 2013 an estimated 85. Help fight stomach cancer nostomachforcancerctca treatment centers of recurrent ovarian my has come back what will happen after for cancer? . Brain cancer symptoms think you may have brain cancer? . Recurrent ovarian cancer. Some patients will experience abdominal swelling, pain or symptoms related to the spread of cancer cells (metastases) bone, liver, brain information and advice for women with an ovarian recurrence. Recurren
Просмотров: 211 Don't Question Me
Living with Stage IV Ovarian Cancer and Thriving
 
04:22
For Mary Sue David, It’s not just about getting through her treatment for stage IV ovarian cancer; it’s about living her life and thriving. Cancer survivor Mary Sue shares her journey with cancer, which has included #breastcancer and #ovariancancer. She talks about her initial fears from her diagnosis, her cancer treatment and how she stays upbeat, living one day at a time. Visit http://www.oacancer.com/living-with-ovarian-cancer-and-thriving/ to read more about Mary Sue's story. About Oncology Associates Oncology Associates provides personalized cancer care and treatment at two Omaha clinics, as well as at clinics in Blair and Norfolk, Nebraska. Please visit http://www.oacancer.com to learn more about their approach to treating cancer. The physicians of Oncology Associates include: * Irina E. Popa, MD #irinapopamd * Laxmi Narayana R. Buddharaju, MD ("Dr. Budd") #drbudd These videos are produced by Oncology Associates to help provide useful cancer information to cancer patients and survivors. Watch more cancer patient and #cancersurvivor videos here - http://www.oacancer.com/oncology-video-center/oncology-associates-patient-stories/
Просмотров: 14080 Oncology Associates
Approaching Recurrent Ovarian Cancer
 
02:42
Bradley J. Monk, MD, FACS, FACOG; Matthew Powell, MD; and David O’Malley, MD, discuss the burden of recurrent ovarian cancer and highlight considerations for second-line therapy.
Просмотров: 150 OncLiveTV
Recurrent Ovarian Cancer; Considerations Beyond the Platinum-Free Interval
 
05:27
Panelists Bradley J. Monk, MD; Robert L. Coleman, MD; Kathleen N. Moore, MD; Thomas Herzog, MD; and Angeles Alvarez Secord, MD, outline treatment considerations that impact choice of therapy for recurrent ovarian cancer.
Просмотров: 1035 OncLiveTV
How to treat Recurrent Cancer
 
15:00
How to treat Recurrent Cancer Current treatment of recurrent cancer is not optimal since medicine ignores that organism resists the tumor. Host resistance may be weak yet it is significant. Obviously if host resistance is high patient requires less drugs and vice versa. Here is an example of therapy which considers host resistance. A woman leaving mammography with a localized breast tumor is treated and tumor is removed. In most women treatment will leave behind tumor remnants too small to be detected. They will grow and later on present as recurrent tumors. The question is how to treat them optimally? I maintain that breast cancer is driven by a virus to which it responds with a tumor. During an aggressive virus infection tumor grows faster and vice versa. I regard tumor as biomarker of two processes: 1. Severity of virus infection 2. Host resistance. Once cancer recurs it is essentially incurable, and the only therapeutic objective is dormancy induction. Cancer dormancy has two manifestations: 1. Tumor stops growing or grows extremely slowly. 2. Tumor is invisible Dormancy induction requires small drug doses. You start with a small dose. Rise it gradually until dormancy is achieved. The initial small dose depends on the time of tumor recurrence. The later tumor recurs the smaller dose is needed
Просмотров: 1268 Gershom Zajicek M.D,
Metastatic Ovarian Cancer
 
06:27
Sylvia De Vries was diagnosed with Stage III-C Ovarian Cancer in October 2003. She had major surgery to remove her cancer-infected reproductive organs and her appendix, followed by 6 rounds of Carboplatin Taxol chemotherapy. She went into remission until December 2009, and commenced Carboplatin Taxol chemotherapy once again for her metastases. After 3 failed treatments, she was put on 6 rounds of Calyx, then Gemzar, which ended up attacking her bone marrow, for which she had a hard time. On August 2, 2010, her Canadian oncologist deemed her terminal and gave her approximately 2 months to live, but she and her husband were not prepared to accept that. Her husband began researching for other alternative cures and was impressed by the Issels Treatment. They also talked to another woman from Windsor, Ontario, who had experienced the treatment. In October 14, 2010 Sylvia came to the Issels Treatment Center in a very frail state, in a wheelchair, and unable to walk. In her own words: "In less than 3 weeks I was able to walk 6 blocks to the ocean from here...The doctors are very caring, they're very aggressive with their treatment, they're very hands-on. You're not a number." Her tumor marker Ca-125 was 141 when she started the Issels Treatment, and in less than 3 weeks it dropped down to 77.9. She feels stronger, more vibrant, and feel alive again. "I know I'm going to be healed. This is the place to be."
Просмотров: 23930 Issels Immunotherapy
Nita Lee on Recurrence of Ovarian Cancer
 
01:06
View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Просмотров: 342 curetoday
When to Add Bevacizumab for Recurrent Ovarian Cancer
 
06:04
Panelists Bradley J. Monk, MD; Matthew A. Powell, MD; Katie Moore, MD; Robert L. Coleman, MD; and Gottfried E. Konecny, MD, discuss the use of bevacizumab for recurrent advanced ovarian cancer, including the recent approval for platinum-sensitive disease.
Просмотров: 634 OncLiveTV
Key Considerations for Treating Recurrent Ovarian Cancer
 
06:18
Panelists Bradley J. Monk, MD; Matthew A. Powell, MD; Gottfried E. Konecny, MD; Robert L. Coleman, MD; and Katie Moore, MD, discuss factors to consider when choosing therapy for recurrent ovarian cancer and several new FDA approvals in this setting.
Просмотров: 521 OncLiveTV
Looking Ahead to Ovarian Cancer Hopes for 2018
 
02:32
Oliver Dorigo, M.D., Ph.D., associate professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond. He shares his excitement about trials that will further investigate the efficacy of PARP inhibitors, and focus on immunotherapy. He speaks with enthusiasm about the potential to “engineer immunity” by taking a person’s T-cells and redirecting them against tumor tissue. Dorigo emphasizes the need for better diagnostic tools to detect ovarian cancer. “The survival rate in stage 1 ovarian cancer, those cancers confined to the ovary, is over 90 percent,” he said. “If we can find technologies that allow us to find those ovarian cancers early on, I think we will make a huge step forward.”
Просмотров: 411 curetoday
Dr. Memarzadeh on Recurrence Rates in Ovarian Cancer
 
01:05
Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.
Просмотров: 490 OncLiveTV
My 6 Times Cancer Recurrence lesson
 
02:49
This video help me to stay positive and focus, help me to believe and love myself the way i am, to be grateful and appreciate what i have got, to be stronger despite of all the difficulties, and to enjoy my moments and take it day by day.
Просмотров: 598 Sogol azharian
Bevacizumab for Recurrent Ovarian Cancer
 
07:32
Panelists Bradley J. Monk, MD; Kathleen N. Moore, MD; Angeles Alvarez Secord, MD; Thomas Herzog, MD; and Robert L. Coleman, MD, describe the use of bevacizumab for recurrent ovarian cancer.
Просмотров: 939 OncLiveTV
Carolyn’s Ovarian Cancer Story | Dana-Farber Cancer Institute
 
02:28
Carolyn was diagnosed with recurrent ovarian cancer. She describes her care and recovery at Dana-Farber, and how that experience has inspired her to become an oncology nurse. Learn more about how the Susan F. Smith Center for Women’s Cancers at Dana-Farber treats patients like Carolyn who have ovarian cancer or other gynecologic cancers: http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Gynecological-Cancer-Treatment-Center.aspx Transcription: Carolyn: My name is Carolyn. I grew up in Boston all my life, and I am a huge Red Sox fan and Patriots fan. In January of 2012, I began nursing school in Nashville, Tennessee. Text: Something didn’t feel right. Carolyn: I began experiencing symptoms of what I thought were a urinary tract infection and was told I needed to go for a CT scan. I came back and received a call from my primary telling me that neither she nor the radiologist were really… They were unsure of what they were looking at. There were masses throughout my abdomen. A couple of days later, after a biopsy, I was told that I had stage 4 ovarian cancer. I met my team from Dana-Farber who ultimately performed the surgery, and then I went on to have six rounds of chemotherapy. I spent the next year or so really recovering from chemotherapy and really just tried to put my life back together and go on living normally. I was getting ready to start school in September 2014 when I started experiencing symptoms that just didn’t feel right. I found there was, in fact, a mass on my colon. It was really discouraging to find out that my cancer was back, but I was also really confident in the care that I was receiving. My doctors had always been up front with me that a recurrence was a possibility. Text: Carolyn was offered a clinical trial for women with recurrent ovarian cancer. Carolyn: I was able to take part in using this ACE-inhibitor, which is traditionally for breast cancer patients, but they had found a link between this working for breast cancer and ovarian cancer. So, I am benefitting from the very research that Dana-Farber does here. Dana-Farber is really like a second home to me. It’s weird to say that I look forward to coming here, but I really do. I can’t say enough about the doctors and the nurses that have cared for me. They’re just wonderful people, and I consider them sort of family now. When I was in nursing school, I used to think I knew what kind of nurse I wanted to be, and after being here at Dana-Farber and seeing the care that I’ve received, I really know what a good nurse is now. My hope is to become an oncology nurse. I would really like to work in the field that I’ve been so immersed in for the last three years.
Просмотров: 2827 Dana-Farber Cancer Institute
About Ovarian Cancer Treatment Lynparza
 
02:45
Lynparza (olaparib) is an approved cancer treatment for certain types of advanced ovarian cancers associated with defective BRCA genes. In this new cancer education video, oncologist Dr. Stephen Lemon talks about how Lynparza works, which types of ovarian cancer patients it benefits and what types of sides effects patients may experience from the treatment. As a PARP inhibitor, #Lynparza is the first drug of its kind to be approved in the US. PARP inhibitors are class of medication that offers promise for treating BRCA related cancers. These drugs block an enzyme used by cells to repair damage to their DNA. For women who do not carry the BRCA mutation, PARP inhibitors may work by keeping cancer cells from repairing themselves once they've been damaged by chemotherapy treatment, while sparing healthy cells. These PARP inhibitors may be very effective for patients with BRCA mutations, as their tumor cells will already have problems repairing DNA and the PARP inhibitors will make this even worse. Lynparza is marketed by AstraZeneca Pharmaceuticals. #DrStephenLemon is a medical oncologist in private practice and is not associated with AstraZeneca. #OvarianCancer #StephenLemonMD Dr Stephen Lemon is medical oncologist who now practices at Overlake Cancer Center Bellevue WA. He produces cancer information videos and web related cancer education projects. He invites you to follow his ongoing work at https://www.lightersideofcancer.com/
Просмотров: 1951 Oncology Associates
Defining Rucaparib’s Value in Recurrent Ovarian Cancer
 
05:11
Shannon Westin, MD, Reflects on the patient’s response to chemotherapy and shares insight on the optimal use of rucaparib, a PARP inhibitor, as maintenance therapy in the setting of advanced epithelial ovarian cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 32 Targeted Oncology
New hope for ovarian cancer
 
03:33
A decade ago, women diagnosed with ovarian cancer had few options for treatment. Surgery, chemotherapy and radiation were standard practice. Those therapies are still in use today, but, thanks to research and new technologies, ovarian cancer patients have additional, and sometimes more effective, options for treatment.
Просмотров: 3225 Mayo Clinic
Ovarian Cancer: Progression and Treatment Options
 
04:41
Dr. Matt McDonald discusses the progression of ovarian cancer and how it is treated. Matt McDonald, MD: Unfortunately in this day and age, the majority of ovarian cancers present at the late stage. Statistically 80% of all ovarian cancers present at an advanced stage either stage 3 or 4. Treatment options for those patients usually requires a combination of a surgery and chemotherapy. New advances in ovarian cancer at this point in time really rely upon what we call adjuvant treatment for ovary cancer and what I mean by that is surgery for ovarian cancer as for several, several decades, its main goal is to what we call surgically remove the cancer and what that means is remove all of the macroscopic or all of the disease that we can see or touch at the time of surgery. Many times we can't remove every single piece of cancer that we can see or feel, but the goal is to leave as little a nodule of cancer behind following surgery and what we strive to do is leave any cancer behind that will be smaller than 1 cm that's the goal and from a surgical standpoint that may require removal of parts of the intestinal tract or urinary tract, etc. The surgery's goal is to remove the large pieces of cancer and leave the smallest amount of residual tumor behind as we can and that's what chemotherapy is for. Chemotherapy works better on small implants of cancer than it does on large implants of cancer. For many patients, we are employing something called intraperitoneal chemotherapy which is when a patient receiving chemotherapy receives a combination of some intravenous chemotherapy which is a standard traditional approach and some patients will receive a combination where they also receive intraperitoneal chemotherapy or a lot of patients consider this a belly wash chemotherapy where there is a port implanted in the abdomen where we infuse chemotherapy directly into the abdominal cavity and in patient that can tolerate and be administered intraperitoneal chemotherapy, it has been shown that these patients actually do better and have a longer survival rate. And so on this day and age that's what most of us strive to do is to have an excellent surgical result followed by a combination intravenous and intraperitoneal chemotherapy. The challenge to the medical environment is to catch ovarian cancer at an earlier stage and there are some new blood tests that are doing a better job with that than we did ten years ago. There are some new screening algorithms or triage algorithms for an ovarian mass that help patients get to a trained professional such as GYN oncologist for their initial operation which in this time still is the most important aspect of a woman's care with ovarian cancer is that her initial diagnosis and initial management is performed by a GYN oncologist. Most notably there are some blood tests. One's called the OVA 1, which is a blood test that screens for five different analytes in a woman's blood to help us dictate whether or not an ovarian mass is cancer or not and that test does do a better job than some of the other more traditional approaches that we use. Again another challenge to women that have been found to have an ovarian mass is to definitely seek out the right physician. The good news is a vast majority of an ovarian mass that is seen on CT scan or ultrasound is benign. It is not a cancer, the vast majority of a time. The challenge for a medical team is to weed out who are those cancers and who is not and certainly seek second opinions, seek out GYN oncologists, if you have an ovarian mass for a second opinion or a surgical consultation, because it's important that you get the best preoperative evaluation in the event that it is a cancer that you are taking care of by the right medical professional. Learn more about Dr. McDonald: http://presbyteriangyncancer.org/?id=5013&sid=123
Просмотров: 10394 Best Doctors
My road to wellness from recurrence of ovarian cancer ~
 
02:42
Just started week one of cycle number 3 ...weekly chemotherapy treatments now.
Просмотров: 593 perriboggs
A New Standard of Care in Recurrent Ovarian Cancer?
 
06:39
Bradley J. Monk, MD, FACS, FACOG; Oliver Dorigo, MD, PhD; Kathleen Moore, MD; Leslie M. Randall, MD, MAS; and Thomas Herzog, MD, discuss the potential impact of the GOG-0213 trial on standard practice in recurrent ovarian cancer space.
Просмотров: 84 OncLiveTV
Approaching Platinum-Refractory Recurrent Ovarian Cancer
 
04:07
Robert L. Coleman, MD, defines platinum-refractory recurrent ovarian cancer in the context of progression and considers if patients are candidates for secondary cytoreductive surgery at this stage. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 25 Targeted Oncology
Ovarian Cancer, When Did It Relapse? - Paula Her Story
 
00:55
Paula shares when her ovarian cancer relapsed.
Просмотров: 214 EmpowHER
Low anterior for recurrent ovarian cancer
 
17:40
Older female with history of ovarian cancer sp TAH BSO now with recurrence in the pelvis that failed chemo. Undergoing laparoscopic resection
Fear of Cancer Recurrence
 
26:30
Просмотров: 196 Swedish
Michelle’s Ovarian Cancer Story
 
09:02
In this segment, Michelle Fladung reflects back on the symptoms that she encountered prior to her diagnosis with ovarian cancer and encourages other women to pay close attention to their bodies and seek the opinions of their healthcare professionals. Angeles Alvarez Secord, MD, highlights the standard protocol for working with a newly diagnosed ovarian cancer patient within her institution.
Просмотров: 4103 curetoday
A New Treatment for Ovarian Cancer
 
01:50
Ovarian cancer is a rare but devastating diagnosis. One, surgeons say, they are finding new ways to treat. And while the technology isn’t new, how it’s being used, is. “We have used it in the past for gastrointestinal tumors of very specific types,” said Dr. Edward Grendys, a gynecologic oncologist on the medical staff of Lee Health. The technology is called HIPEC, which stands for hyperthermic intraperitoneal chemotherapy. A cancer treatment that’s now able to be used on patients with ovarian cancer. “With the installation of heated chemotherapy, we actually are showing another step forward in both survival as well as progression-free intervals in women who have advanced disease,” said Dr. Grendys. Patients who qualify for this procedure will typically undergo chemotherapy before coming to surgery. Once in surgery, doctors will first use a laparoscope to look for any remaining signs of cancer. “We will place a laparoscope on the inside. We visually can inspect the abdominal cavity, with that we can make a judgment on if we can remove the tumor, and about 80 percent of the time we can,” he said. Then surgeons will activate the HIPEC machine. “Two catheters are placed into the abdominal cavity. We close up the abdominal cavity as if we are completing the operation and then literally cycle heated chemotherapy through the abdominal cavity-that is preheated, predetermined, and premeasured,” said Dr. Grendys. The chemotherapy will cycle through the abdomen for 90 minutes to eliminate any remaining cancer cells. After that, surgeons remove the HIPEC and complete the operation. After surgery, patients may need three more cycles of chemotherapy before they are finished with treatment. A new procedure that doctors say is saving lives and giving hope to women with advanced stages of ovarian cancer. View More Health Matters video segments at LeeHealth.org/Healthmatters/ Lee Health in Fort Myers, FL is the largest network of health care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For more than 100 years, we’ve been providing our community with personalized preventative health services and primary care to highly specialized care services and robotic assisted surgeries. Lee Health - Caring People. Inspiring Care. Visit LeeHealth.org
Просмотров: 5579 Lee Health
Laparoscopic diagnostic of ovarian cancer reccurens
 
35:16
Peritoneal & lymph node recurrence 7 years after T3bN0M0 ovarian cancer treatment (hysterectomy, omentectomy & 6 courses of chemotherapy, 2008). Laparoscopic biopsy of pelvic mass, paracaval & external iliac lymph nodes.
Просмотров: 2226 Dr. Sergey Baydo
Rucaparib boosts PFS in BRCA-mutated recurrent ovarian cancer
 
03:29
Sandro Pignata, MD, PhD, from the IRCCS National Cancer Institute, Naples, Italy, presents a summary of the data from the ARIEL 3 trial on rucaparib in ovarian cancer patients, presented at the European Society for Medical Oncology (ESMO) 2017 Conference in Madrid, Spain. Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to the late-breaking results. Most ovarian cancer presents as advanced disease and 80% of those patients will recur after first line treatment. Patients often respond again to chemotherapy, particularly platinum-based, but they almost inevitably relapse again and eventually die of their disease. Maintenance treatments are needed to reduce recurrence in patients who have already relapsed. The PARP enzyme helps to initiate the repair of DNA damage so that cells can continue to divide. DNA repair processes are inherently impaired in tumour cells with BRCA mutations. PARP inhibitors, such as rucaparib, block DNA repair and cells with BRCA mutations die. Dr Pignata further discusses how these positive data will benefit patients, giving them more choice with effective treatments.
Просмотров: 69 VJOncology
OVARIAN CANCER: TREATMENT STRATEGIES FOR PLATINUM-SENSITIVE RECURRENCE
 
05:36
E. TIMOTHEADOU, ASSISTANT PROFESSOR IN MEDICINE & ONCOLOGY, ARISTOTLE UNIVERSITY OF THESSALONIKI, 5ο ΜΕΤΕΚΠΑΙΔΕΥΤΙΚΟ ΣΕΜΙΝΑΡΙΟ ΚΛΙΝΙΚΗΣ ΚΑΙ ΕΡΕΥΝΗΤΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ
Просмотров: 96 ELIEKchannel
Dr Meena Shah - Care  & Treatment Of Ovarian Cancer Recurrence - Wellness & Health Care
 
02:53
Care & Treatment Of Ovarian Cancer Recurrence Interview with Dr.Mithun Shah Medical Oncologist,Ahmedabad
Просмотров: 150 Dr Meena Shah
Finding Signs of Ovarian Cancer
 
05:07
From http://www.beetmedicine.tv/2009/04/ovarian-cancer-is-not-silent-cancer-it-whispers.html: Ovarian cancer is rare and usually discovered at a late stage. The signs are symptoms are subtle and not dissimilar from other abdominal or pelvic complaints. The key is that they are persistent. Dr. Poynor describes this not as silent cancer but, a cancer which whispers. Workup includes a pelvic exam, a transvaginal ultrasound and possibly a CAT scan. CA 125 is a blood test which is useful in following women who have been treated for an ovarian cancer to monitor a recurrence. It is not sensitive enough to detect early ovarian cancer nor specific enough because it may be elevated in benign conditions. But, it can be used until better markers become available. Peter Pressman, MD Interviewee: Elizabeth Poynor, MD, PhD FACOG Gynecologic Oncologist
Просмотров: 55932 BeetMedicineTV
Kym's story - Fear of cancer recurrence
 
10:10
While fear of cancer recurrence may never go away completely there are ways to manage it. In this video you will hear from Kym about how she copes with her fears of cancer recurrence.
Просмотров: 5106 Breast Cancer Network Australia
Recurrance in Stage III & IV Ovarian Cancer - Paula J. Anastasia, RN, MN
 
04:35
An interview with Paula J. Anastasia, RN, MN discussing recurrance in Ovarian Cancer; Importance of Clinical Trials; PARP Inhibitors - ONS 2010
Просмотров: 12788 Oncology.TV
Ovarian Cancer Survival Rate   YouTube
 
00:25
Просмотров: 51 Rodriguez Taylor
Secondary Debulking in Recurrent Ovarian Cancer
 
04:49
Panelists Bradley J. Monk, MD; Katie Moore, MD; Robert L. Coleman, MD; Gottfried E. Konecny, MD; and Matthew A. Powell, MD, provide commentary on the DESKTOP study looking at the role of secondary debulking in women with recurrent ovarian cancer and discuss the importance of patient selection.
Просмотров: 379 OncLiveTV
My CT scan results after 6 rounds of chemo - Metastatic Breast Cancer (lungs)
 
05:57
Fast forward to today, after 6 rounds of chemo (sorry I haven't had time to edit and upload my vlogs but I'll definitely go back in time later), I finally receive my CT scan results which determine whether or not I need more chemo, or if I can move on to hormone therapy... the results? POSITIVE!!! My 6th round was finally, MY LAST!!! In this video I show the anxiety a cancer patient gets waiting for results. It's tough to watch but it's real! Read my blog at http://www.nalie.ca/blog SUBSCRIBE: http://www.youtube.com/nalieagustin FOLLOW ME: http://www.instagram.com/nalieagustin LIKE ME: http://www.facebook.com/officialnalie TWEET ME: http://www.twitter.com/nalieagustin DOWNLOAD MY GUIDE: http://www.chemosecrets.ca
Просмотров: 248057 Nalie Agustin
Moving Beyond the Fear of Recurrence
 
03:34
Young breast cancer survivors discuss their fear of a cancer recurrence now that that they have completed treatment
Просмотров: 7246 Johns Hopkins Medicine
Recurrent Ovarian Cancer: Selecting Second-Line Therapy
 
05:01
Shannon Westin, MD, provides considerations for selecting a regimen to treat recurrent platinum-sensitive epithelial ovarian cancer including maintenance therapy and controlling elevation in liver enzymes. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 41 Targeted Oncology
Niraparib as maintenance for platinum-sensitive ovarian cancer - results from ENGOT-OV16/NOVA trial
 
01:50
Sven Mahner, MD, PhD of the University Medical Center Hamburg-Eppendorf Hamburg, Germany talks about the Phase III trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial, NCT01847274). Dr Mahner explains that ovarian cancer is a common disease, which in the first-line setting, needs extensive surgery and chemotherapy. However, the majority of patients recur and they are re-treated with chemotherapy. The trial looked at maintenance therapy with niraparib after recurrent chemotherapy. According to Dr Mahner, they observed a large benefit for patients receiving niraparib maintenance in both, the germline BRCA (gBRCA) mutation and non-gBRCA mutated patient populations. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
Просмотров: 186 VJOncology
CA-125 Blood Test:  Normal range & Its Role as an  Ovarian Cancer Test
 
02:34
#CA125#Ovariancancer Full form of CA 125 is Cancer Antigen 125.It is a tumor marker for ovarian cancer. Normal levels are less than 35 U/L. Increased levels are seen in ovarian cancer. CA 125 is a mucinous protein present on the epithelial surfaces of the eye, respiratory tract, ovaries CA 125 is specifically seen increased in epithelial cell cancers. More over it has higher chances of being positive only in advanced stages of cancer .It is NOT USED for screening of ovarian cancer as it is not sensitive and specific. It needs to correlated clinically and always should be correlated with other diagnostic tests. Role in Endometriosis: It is not a sensitive marker for endometriosis. Levels are greater than 35 are especially seen in stage 3&4 of endometriosis. Levels greater than 100 U/mL indicate extensive pelvic adhesion's. However the most accurate test for diagnosis of endometriosis is Laproscopy(Direct Visualisation). NEW MARKER HE4 - Human Epididymis Protein 4 (HE4) is a relatively new marker for Ovarian malignancy and indicates gene over expression. It is used to monitor recurrence & disease progression in patients with Epithelial ovarian malignancy. HE4 when used in conjunction with CA 125 helps in estimating the Risk Of Ovarian Malignancy (ROMA) in premenopausal / postmenopausal females presenting with an adnexal mass. More info : https://www.interpretyourbloodtests.com www.facebook.com/interpretyourbloodtests/ Music from www.bensound.com
Просмотров: 2329 Interpret Your Blood Tests
How I Stopped Living in Fear of Cancer Recurrence - Happy Chemo!
 
08:19
Cancer Survivors often fall into the trap of FEAR when it comes to reccurrence. I know I did for a while and it wasn't fun. Here's some insights that helped me get out of the vicious cycle. Get more at http://happychemo.com
Просмотров: 2249 Happy Chemo!
Update on the Management of Recurrent Ovarian Cancer
 
15:18
For CME credit visit http://www.i3health.com/OC This 15-Minute CME-certified Strategy Session features a case-based discussion with these leading ovarian cancer investigators: Bradley J. Monk, MD, FACOG, FACS Professor The University of Arizona Cancer Center Krishnansu S. Tewari, MD, FACOG, FACS Professor and Director of Research University of California, Irvine Medical Center
Просмотров: 932 i3health
Not on My Watch PSA With Cobie Smulders
 
01:01
While Cobie has been in remission for more than 10 years, she knows that the majority of women with ovarian cancer will see it return (also known as recurrence). That's why, in partnership with TESARO, Cobie is working to educate and empower women with recurrent ovarian cancer about their treatment options, and to let them know they no longer have to just "wait and watch." Learn more at http://ssshare.it/GKdE.
Просмотров: 1179 Not on My Watch
Role of HIPEC in advanced Ovarian & Colorectal Cancer - Dr. Somashekhar S P
 
01:37
Unfortunately in India Ovarian cancer patients come in stage 3C. colorectal cancer patients also come quite late. if you have a colorectal cancer stage 4 with peritoneal spread Conventional treatment will not cure them. in patients who responded quite well to the chemo the cancer will not spread out side of the tummy. For Recurrent ovarian cancer patients cytoreduction surgery with hipec is the only treatment which can save them
Sequencing for Treatment for Recurrent Ovarian Cancer
 
06:44
Panelists Gottfried E. Konecny, MD; Bradley J. Monk, MD; Robert L. Coleman, MD; Matthew Powell, MD; and Katie Moore, MD, discuss the need for individualized treatment of recurrent ovarian cancer and sequencing through multiple lines of therapy, as well as the QUADRA and ARIEL4 trials.
Просмотров: 650 OncLiveTV
Immunotherapy for Gynecological Cancers
 
54:48
This presentation summarizes the current progress in immunotherapy for ovarian, endometrial and cervical cancer. Recent clinical trial data will be reviewed, and promising novel therapeutic approaches will be discussed. Speaker: Oliver Dorigo, MD, PhD
Просмотров: 1027 Stanford Health Care